title: Synergistic effect of pyrrolidine dithiocarbamate and cisplatin in human cervical carcinoma.
abstract: We aimed to delineate how pyrrolidine dithiocarbamate (PDTC) affects nuclear factor κB (NF-κB) and to determine its antitumor activity alone and in combination with cisplatin in human cervical cancer SiHa cells. The SiHa cells were treated with various concentrations of PDTC and/or cisplatin at various time intervals. Cell proliferation and apoptosis were determined using a water-soluble tetrazolium salt 8 assay and flow cytometry. Electrophoretic mobility shift assay was used to assess NF-κB activity. Pyrrolidine dithiocarbamate (2.5-100 µmol/L) was found to inhibit the growth of SiHa cell lines. Cisplatin (0.01-20.0 μg/mL) and PDTC (2.5-20.0 µmol/L) combined demonstrated additive inhibitive effects on cell growth and increased the level of apoptosis. In addition, PDTC blocked cisplatin-induced activation of NF-κB, leading to enhanced apoptosis and increased chemosensitivity to cisplatin. Taken together, PDTC has significant potential as a chemotherapy agent, alone or in combination with cisplatin.
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China Department of Obstetrics and Gynecology, the People's Hospital of Wenzhou, Wenzhou 325000, China.
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Zheng
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
authors.forename: Jieqiang
authors.initials: J
authors.lastname: Lv
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Shen
authors.affiliation: Department of Obstetrics and Gynecology, the People's Hospital of Wenzhou, Wenzhou 325000, China.
authors.forename: Yumei
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
authors.forename: Qingfeng
authors.initials: Q
authors.lastname: Zhou
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China.
authors.forename: Wenwen
authors.initials: W
authors.lastname: Zhang
authors.affiliation: Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, China zjwzzxq@163.com.
authors.forename: Xueqiong
authors.initials: X
authors.lastname: Zhu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000975:Antioxidants / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D016328:NF-kappa B / Q000037:antagonists & inhibitors*; D011759:Pyrrolidines / Q000008:administration & dosage*; D013859:Thiocarbamates / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D016328:NF-kappa B; D011759:Pyrrolidines; D013859:Thiocarbamates; C020972:pyrrolidine dithiocarbamic acid; D002945:Cisplatin
keywords: cervical cancer SiHa cells; chemosensitivity; cisplatin; nuclear factor κB; pyrrolidine dithiocarbamate